SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-013665
Filing Date
2022-08-01
Accepted
2022-08-01 16:01:59
Documents
67
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q cere-20220630.htm   iXBRL 10-Q 3326485
2 EX-31.1 cere-ex31_1.htm EX-31.1 18885
3 EX-31.2 cere-ex31_2.htm EX-31.2 18871
4 EX-32.1 cere-ex32_1.htm EX-32.1 10774
5 EX-32.2 cere-ex32_2.htm EX-32.2 10780
6 GRAPHIC img32106905_0.jpg GRAPHIC 112035
  Complete submission text file 0000950170-22-013665.txt   10404369

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT cere-20220630_def.xml EX-101.DEF 184819
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT cere-20220630_cal.xml EX-101.CAL 47290
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cere-20220630_pre.xml EX-101.PRE 307404
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cere-20220630_lab.xml EX-101.LAB 401535
11 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cere-20220630.xsd EX-101.SCH 47410
61 EXTRACTED XBRL INSTANCE DOCUMENT cere-20220630_htm.xml XML 2024155
Mailing Address 222 JACOBS STREET SUITE 200 CAMBRIDGE MA 02141
Business Address 222 JACOBS STREET SUITE 200 CAMBRIDGE MA 02141 844-304-2048
Cerevel Therapeutics Holdings, Inc. (Filer) CIK: 0001805387 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39311 | Film No.: 221124700
SIC: 2834 Pharmaceutical Preparations